Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Deshpande, J. Katz, D. Solomon, E. Yelin, D. Hunter, S. Messier, L. Suter, E. Losina (2016)
Number of Persons With Symptomatic Knee Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and ObesityArthritis Care & Research, 68
T. Vos, A. Abajobir, C. Abbafati, K. Abbas, K. Abate, F. Abd-Allah, A. Abdulle, Teshome Abebo, S. Abera, V. Aboyans, L. Abu-Raddad, I. Ackerman, Abdullahi Adamu, O. Adetokunboh, M. Afarideh, A. Afshin, S. Agarwal, R. Aggarwal, Anurag Agrawal, S. Agrawal, A. Kiadaliri, H. Ahmadieh, M. Ahmed, Amani Aichour, Ibtihel Aichour, Miloud Aichour, Sneha Aiyar, R. Akinyemi, N. Akseer, F. Lami, Fares Alahdab, Z. Al‐Aly, K. Alam, N. Alam, Tahiya Alam, D. Alasfoor, K. Alene, R. Ali, R. Alizadeh-Navaei, A. Alkerwi, F. Alla, P. Allebeck, Christine Allen, F. Al-Maskari, Rajaa Al-Raddadi, U. Alsharif, M. Kivimäki, A. Meretoja, T. Meretoja, E. Weiderpass, Gbd Prev (2017)
Global, regional, and national incidence and prevalence, and years lived with disability for 328 diseases and injuries in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Spierings, J. Fidelholtz, Gernot Wolfram, Michael Smith, Mark Brown, C. West (2013)
A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or kneePAIN®, 154
Mark Brown, F. Murphy, D. Radin, I. Davignon, Michael Smith, C. West (2013)
Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.Arthritis and rheumatism, 65 7
T. Schnitzer, Richard Easton, Shirley Pang, D. Levinson, G. Pixton, L. Viktrup, I. Davignon, Mark Brown, C. West, K. Verburg (2019)
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.JAMA, 322 1
Tive (2019)
Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip.J Pain Res, 12
M. Cisternas, L. Murphy, J. Sacks, D. Solomon, D. Pasta, C. Helmick (2016)
Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population‐Based SurveyArthritis Care & Research, 68
M. Hochberg, L. Tive, S. Abramson, E. Vignon, K. Verburg, C. West, Michael Smith, D. Hungerford (2016)
When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development ProgramArthritis & Rheumatology, 68
A. Kivitz, J. Gimbel, C. Bramson, M. Nemeth, D. Keller, Mark Brown, C. West, K. Verburg (2013)
Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back painPAIN®, 154
B. Zencirci (2010)
Postdural puncture headache and pregabalinJournal of pain research, 3
E. Losina, G. Michl, J. Collins, D. Hunter, J. Jordan, E. Yelin, A. Paltiel, J. Katz (2016)
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration.Osteoarthritis and cartilage, 24 5
E. Ekman, J. Gimbel, A. Bello, Michael Smith, D. Keller, K. Annis, Mark Brown, C. West, K. Verburg (2014)
Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus NaproxenThe Journal of Rheumatology, 41
N. Lane, T. Schnitzer, C. Birbara, M. Mokhtarani, D. Shelton, Mike Smith, Mark Brown (2010)
Tanezumab for the treatment of pain from osteoarthritis of the knee.The New England journal of medicine, 363 16
F. Watt, M. Gulati (2017)
New Drug Treatments for Osteoarthritis: What is on the Horizon?European medical journal. Rheumatology, 2 1
Jeffrey Rollman, James Heyward, Lily Olson, P. Lurie, J. Sharfstein, G. Alexander (2019)
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl ProductsJAMA, 321
Opinion EDITORIAL Jeffrey N. Katz, MD, MSc Osteoarthritis (OA) is a painful, disabling condition that treated concomitantly with tanezumab and NSAIDs than in arises from damage to cartilage, synovium, subchondral those treated with tanezumab without NSAIDs. Thus, in bone, and other joint structures. An estimated 300 mil- subsequent trials, tanezumab-treated patients have not been lion people worldwide have OA, including 30 million indi- permitted to receive NSAIDs, and those with lesions, such as viduals in the United States, subchondral insufficiency fractures or avascular necrosis, of whom more than 14 mil- which might be precursors to rapidly progressive OA, have Related article page 37 lion have symptomatic, radio- been excluded. Also, reviews of the cases of rapidly progres- graphically documented knee OA. Despite the enormous sive OA and total joint replacement occurring in tanezumab prevalence, cost, and disability associated with OA, no trials indicate that 44% of these events occurred in nonindex treatments are available to slow or reverse the inexorable joints (joints other than the one that prompted the patient destruction of joint structures that underlie the pain and to seek care). This is an important finding: A patient who disability of OA (although several agents are in various
JAMA – American Medical Association
Published: Jul 2, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.